Core Insights - LivePerson has appointed Nathan "Tripp" Lane to its Board of Directors, bringing extensive experience in technology strategy and business transformation [1][2][3] Company Overview - LivePerson (NASDAQ: LPSN) is a leader in predictable conversational AI and digital transformation, serving major brands with its Conversational Cloud platform [4] - The company facilitates nearly a billion conversational interactions monthly, providing valuable data analytics and safety tools [4] Board Appointment - Tripp Lane's background includes founding Delancey Cove LLC, advising on strategic and operational matters, and holding board positions in various technology companies [3] - His appointment is seen as a strategic move to enhance execution and shareholder value for LivePerson [2][3]

Core Insights - The FDA has mandated the allocation of at least $200 million from its user fees to enforce regulations on electronic nicotine delivery systems (ENDS), including a focus on illegal vape products [2][3] - Ispire Technology and IKE Tech are collaborating to develop technological solutions to enhance product verification and compliance in the vaping industry [4][8] Regulatory Developments - The FDA's new directive includes a requirement to update enforcement guidance regarding flavored disposable vapes and to report progress to Congress biannually [2] - A multi-agency task force will be established to combat the influx of illegal ENDS products entering the U.S. [2] Industry Response - IKE Tech's president highlighted the need for improved standards in an industry plagued by illegal products, noting that 90% of vapes on shelves are illegal [3] - Ispire's co-CEO emphasized the importance of pairing enforcement with proactive technological standards to combat illicit imports and support legitimate businesses [6] Technological Innovations - IKE Tech is developing blockchain-secured smart authentication tags and AI-driven age-verification solutions to ensure compliance and product legitimacy [4][8] - The jointly developed blockchain-enabled System-on-a-Chip aims to provide real-time identity validation at the device level, ensuring only verified adults can activate a vape [7][8] Market Context - The flavored vape market is valued at approximately $30 billion, and the companies aim to bring it back under lawful control through enhanced regulatory compliance and technological solutions [7]

Accessibility StatementSkip Navigation RAMAT-GAN, Israel, Nov. 17, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today results from its joint research with Virginia Commonwealth University (VCU) evaluating Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. The collaboration is based on breakthrough findings pub ...

Accessibility StatementSkip Navigation IRVING, Texas, Nov. 17, 2025 /PRNewswire/ -- Caris Life Sciences®Â (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will attend the following investor conferences: Contact [email protected] to schedule meetings. About Caris Life SciencesCaris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is acti ...

Core Insights - Mynd.ai, through its subsidiary Promethean, is launching an AI-powered integration with Augment Me Inc. within the Explain Everything platform, set for release in December 2025, enhancing educational experiences with real-time insights and personalized support [1][2][4]. Product Features - The integration will transform traditional digital whiteboarding into a dynamic learning experience, providing educators with near real-time insights into student engagement and cognitive readiness without additional logins or setup [2][6]. - Key features include actionable recommendations for improved focus and well-being, adaptive feedback tailored to each session, and seamless integration within the Explain Everything platform [6][4]. Strategic Vision - The launch exemplifies Promethean's strategic vision to enhance customer value and enrich learning experiences, positioning Mynd.ai at the forefront of educational transformation [3][5]. - Promethean aims to provide intuitive tools that save educators time, deepen insights, and foster meaningful student engagement [5][4].

Core Insights - Traditional Bank has selected Jack Henry to enhance its technology framework, improve employee and customer experiences, and support future growth [1][3] - Traditional Bank, founded in 1902, has grown to operate 19 branches with total assets of $2.4 billion, focusing on organic growth and community needs [2] Company Transition - Traditional Bank is moving from an in-house IT environment to Jack Henry's hosted core processing platform, allowing IT staff to focus on strategic initiatives like AI and digital innovation [3] - The transition aims to minimize errors and streamline processes through automation, enabling frontline staff to dedicate more time to customer interactions [3] Strategic Alignment - The decision to partner with Jack Henry was influenced by their open ecosystem and integration capabilities with over 950 API-integrated fintechs, which is essential for Traditional Bank's operations [4] - Traditional Bank's leadership emphasized the importance of a technology provider that is forward-looking and capable of supporting unique initiatives without creating obstacles [4] Industry Context - Jack Henry is recognized as a financial technology company that fosters connections between financial institutions and their clients, offering a collaborative ecosystem for innovation [4] - The company has been providing technology solutions for nearly 50 years, empowering approximately 7,400 clients to innovate and compete effectively in the evolving financial landscape [4]

Accessibility StatementSkip Navigation RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 /PRNewswire/ -- Charles & Colvard, Ltd. (OTC: CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab-grown diamonds, today announced a strategic partnership with VideoShops, a next-generation social commerce network built to change how commerce flows throughsocial with over 50,000 sellers transforming how people shop, share, and engage with today's consumers. "We believe this ...

Core Insights - Anixa Biosciences has received approval from the WHO for the non-proprietary name "liraltagene autoleucel" for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant milestone in its development and potential commercialization [1][2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) therapy, which targets the follicle stimulating hormone receptor (FSHR) expressed on ovarian cells and certain cancer cells [3][4] Clinical Development - The ongoing Phase 1 trial of liraltagene autoleucel is designed to evaluate safety, identify the maximum tolerated dose, and monitor clinical activity in adult women with recurrent ovarian cancer who have progressed after at least two prior therapies [3][4] - The trial is being conducted in partnership with Moffitt Cancer Center, a leader in cancer immunotherapy [2][4] Future Directions - The approval of the non-proprietary name allows Anixa to establish a universally recognized name for its CAR-T therapy, facilitating clearer identification and safe prescription of the drug [2][3] - The company plans to transition to using the name liraltagene autoleucel, or lira-cel, in future communications [2]

Accessibility StatementSkip Navigation First-line treatment with TREMFYA shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety profile More than half of TREMFYA-treated patients across both dose groups achieved a 50% improvement in signs and symptoms of psoriatic arthritis by Week 48 in the Phase 3b APEX study NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new d ...

Investor Contact:Najim Mostamand, CFAVice President, Investor Relations757-431-7913[email protected] SOURCE PRA Group, Inc. Accessibility StatementSkip Navigation NORFOLK, Va., Nov. 17, 2025 /PRNewswire/ -- PRA Group, Inc. (Nasdaq: PRAA) (the "Company"), a global leader in acquiring and collecting nonperforming loans, announced today that management is scheduled to participate at the following investor events: The Citizens Financial Services ConferenceDate: Tuesday, November 18, 2025Format: 1x1 and small g ...